Comparative Pharmacology
Head-to-head clinical analysis: KADIAN versus PALLADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KADIAN versus PALLADONE.
KADIAN vs PALLADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; modulates pain perception and emotional response to pain.
Agonist at mu-opioid receptors, modulating pain perception via central and peripheral pathways.
20-100 mg orally every 12 hours; titration based on pain severity and prior opioid exposure.
Immediate-release: 4-8 mg orally every 4-6 hours as needed for pain; extended-release: 8 mg orally every 12 hours, titrated based on response and tolerance.
None Documented
None Documented
Terminal elimination half-life of morphine: 2–4 hours; KADIAN extended-release formulation: effective half-life ~12 hours due to prolonged absorption, dosing q12h or q24h
Terminal elimination half-life is approximately 18 hours (range 12-24 h); supports extended dosing intervals.
Renal: primarily as morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G); ~90% of total elimination is renal, with 10% biliary/fecal
Primarily renal (90%) as unchanged drug and glucuronide conjugate; ~10% biliary/fecal.
Category C
Category C
Opioid Analgesic
Opioid Analgesic